Oxytocin Add-on for Stable Depressed Patients

NCT ID: NCT01211756

Last Updated: 2019-09-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-10-31
• Study Completion Date: 2015-12-31

Brief Summary

The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve depression symptoms in patients with Major Depressive Disorder (MDD) or Dysthymia Disorder.

Detailed Description

Depression patients treated with even the best currently available antidepressant drugs continue to experience significant symptoms. There is a strong need for better treatments including treatments that can safely be given adjunctively with concurrent antidepressants in order to improve overall efficacy of treatment.

Oxytocin is a neurohypophyseal peptide best known for its role as a neurohormone involved in parturition and lactation. In addition to these well established peripheral effects, there is a compelling body of converging evidence indicating that oxytocin plays a critical role in the regulation of a number of diverse centrally-mediated behavioral and cognitive processes that are highly relevant to mood regulation and mood disorders, including social attachment (Argiolas and Gessa 1990; McCarthy and Aaltemus 1997).

Each subject will be enrolled for a 8 week treatment period after a screening phase. Study procedure involves weekly clinic visits as an outpatient. Twenty patients will be randomly assigned to either 40 IU oxytocin twice daily or vehicle placebo. After 4 weeks, treatments will be crossed over such that subjects that received oxytocin will receive placebo and vice versa. The study ratio is 1:1. Dose of oxytocin is based upon previous studies in humans showing improvement in psychiatric populations related changes in behavior and brain function (Kosfeld et al, 2005; Kirsch 2005; Heinrich M 2003).

The total study duration for each individual subject will be approximately 9 weeks, which includes up to 31-day screening period, a baseline (randomization) visit, four week treatment period, 1 week washout, baseline 2 visit, and four weeks cross over treatment.

Conditions

Major Depressive Disorder; Dysthymia Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Oxytocin

20 IU of intranasal oxytocin twice per day for the first week, 40 IU of intranasal oxytocin twice per day for the following 3 weeks, one week wash out, 4 week placebo trial.

Group Type: EXPERIMENTAL

Oxytocin

Intervention Type: DRUG

20 IU BID for one week, followed by 40 IU BID for 3 weeks.

Placebo

Four week placebo trial, one week wash out, 20 IU of intranasal oxytocin twice per day for one week, 40 IU of intranasal oxytocin twice per day for 3 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

20 IU BID for one week, followed by 40 IU BID for 3 weeks.

Interventions

Oxytocin

20 IU BID for one week, followed by 40 IU BID for 3 weeks.

Intervention Type: DRUG

Placebo

20 IU BID for one week, followed by 40 IU BID for 3 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adult men or women, 18 years of age or older.

2. Meet DSM-IV criteria for Major Depressive Disorder or Dysthymia Disorder

3. Women of childbearing potential must test negative for pregnancy at the time of enrollment based on urine pregnancy test and agree to use a reliable method of birth control during the study.

4. Must be on a therapeutic dose of 1 or 2 antidepressants with no major dose changes for at least 4 weeks at randomization.

5. MADRS score of >17 at randomization

6. Have a Clinical Global Impressions-Severity (CGI-S) scale score of at least 4 (moderately ill) at baseline.

7. Must be able to communicate effectively with the investigator and study coordinator and have the ability to provide informed consent.

8. Must be able to use nasal spray

9. Must demonstrate an acceptable degree of compliance with medication and procedures in the opinion of the investigator. (If patient cannot then he/she will be considered for the acute only portion of this study.)

Permitted:

Subjects on up to 2 sleep medication (diphenhydramine, zolpidem, zaleplon, or diazepam), at a reasonable dose, as judged by the investigator, is permitted in this study.

Minor adjustments in sleep medication is acceptable. Patients will be asked to notify the study doctor of any changes to sleep aids.

Exclusion Criteria

Subjects will be excluded from the study of they meet any of the following criteria:

1. Are pregnant or are breastfeeding (negative pregnancy test at screening)

2. A urine drug screen performed at screening must not show evidence of recent use of drugs of abuse

3. Any active medical condition that in the opinion of the investigator will interfere with the objectives of the study

4. Are unsuitable in any way to participate in this study, in the opinion of the investigator.

5. Another current DSM-IV diagnosis other than Major Depressive Disorder or Dysthymia Disorder

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

David Feifel

OTHER

Sponsor Role: lead

Responsible Party

David Feifel

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

David Feifel, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Diego

Locations

UCSD Medical Center

San Diego, California, United States

Countries

United States

Other Identifiers

Oxytocin Depression

Identifier Type: -

Identifier Source: org_study_id